Ageas completes the acquisition of Saga's Underwriting Business
The completion of the acquisition of AICL represents the first milestone towards the establishment of a 20-year partnership with Saga Services Limited (SSL) for the distribution of personal lines Motor and Home insurance products to Saga's customers, as communicated on 16 December 2024 (read the press release).
Advertisement
The acquisition and the distribution agreement with Saga, the UK specialist provider of products and services to people aged over 50, aligns perfectly with Ageas's Elevate27 strategy, to capitalise on its robust Non-Life presence across Europe, while accelerating solutions targeted at an ageing population, a rapidly expanding customer segment where the Group and Ageas UK already have real strength and expertise. Furthermore, it presents Ageas with the opportunity to enhance its position as a leading personal lines insurer in the UK.
The overall consideration for the acquisition is approximately GBP 67 million – consistent with prior communications, and to be paid out between acquisition and the operational start date of the partnership. The overall Solvency II impact, including the Affinity Partnership, remains aligned with the previously communicated – 5%.
Ageas is a Belgian rooted listed international insurance Group with a heritage spanning of 200 years. It offers Retail and Business customers Life and Non-Life insurance products designed to suit their specific needs, today and tomorrow, and is also engaged in reinsurance activities. As one of Europe's larger insurance companies, Ageas concentrates its activities in Europe and Asia, which together make up the major part of the global insurance market. It operates successful insurance businesses in Belgium, the UK, Portugal, Türkiye, China, Malaysia, India, Thailand, Vietnam, Laos, Cambodia, Singapore, and the Philippines through a combination of wholly owned subsidiaries and long-term partnerships with strong financial institutions and key distributors. Ageas ranks among the market leaders in the countries in which it operates. It represents a staff force of about 50,000 people and reported annual inflows of EUR 18.5 billion in 2024.
Attachment
PDF version of the press release
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Trade Tensions Boost the Dollar
The dollar index (DXY00) today is up by +0.14% at a 1-week high. The weakness in stocks today has boosted some liquidity demand for the dollar. Also, comments from President Trump that he will start announcing unilateral tariff rates in the coming days on dozens of countries are lifting the dollar, as concerns rise that rising tariffs will boost inflation and prevent the Fed from cutting interest rates. Gains in the dollar are limited after President Trump signed the reconciliation bill into law last Friday. The nonpartisan Congressional Budget Office estimates that the bill will add $3.4 trillion to US budget deficits over the next decade. The fiscal stimulus from the bill will be a net positive for the US economy, but the higher deficit is negative for the dollar as it increases the risk of an eventual debt crisis in the United States and reduces foreign investor confidence in the United States. Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! The markets are discounting a 5% chance of a -25 bp rate cut at the July 29-30 FOMC meeting. EUR/USD (^EURUSD) today is down by -0.37%, mainly due to dollar strength. Also, weaker-than-expected Eurozone economic news is weighing on the euro after Eurozone May retail sales fell more than expected. Limiting losses in the euro is the jump in the Eurozone's July Sentix investor confidence index to a nearly 3.50 year high, and the unexpected increase in German May industrial production. The Eurozone July Sentix investor confidence index rose +4.3 to a nearly 3.50-year high of 4.5, stronger than expectations of 1.0. Eurozone May retail sales fell -0.7% m/m, weaker than expectations of -0.6% m/m and the biggest decrease in 1.75 years. German May industrial production unexpectedly rose +1.2% m/m, stronger than expectations of a -0.2% m/m decline. Swaps are pricing in a 6% chance of a -25 bp rate cut by the ECB at the July 24 policy meeting. USD/JPY (^USDJPY) today is up by +0.88%. The yen fell to a 1.50-week low against the dollar today on concern that higher US tariffs on Japanese exports will hurt the Japanese economy. Also, the rising tariffs may prevent the BOJ from raising interest rates further. Last Tuesday, President Trump said that a trade deal with Japan is unlikely, indicating that the country will likely face a tariff of 30%, 35%, or "whatever the number is that we determine." Higher T-note yields today are also weighing on the yen. The Japan May leading index CI rose +1.1 to 105.3, stronger than expectations of 105.2. Japan May labor cash earnings rose +1.0% y/y, weaker than expectations of +2.4% y/y. August gold (GCQ25) today is down -15.20 (-0.45%), and September silver (SIU25) is down -0.304 (-0.82%). Precious metals are under pressure today from a stronger dollar. Also, higher global bond yields today are weighing on precious metals. In addition, industrial metals demand concerns are weighing on silver prices after President Trump said that he will impose an additional 10% tariff on countries aligned with BRICS block, which includes Brazil, China, South Africa, and India, with no exemptions. Today's stock market weakness is boosting some safe-haven demand for precious metals. Also, trade tensions are boosting safe-haven demand for precious metals after President Trump pledged to start issuing unilateral tariff rates in the coming days on dozens of countries. Fund buying of silver is supporting silver prices as silver holdings in ETFs rose to a 2.75-year high last Friday. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Business Upturn
10 hours ago
- Business Upturn
CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology
Business Wire India CorFlow Therapeutics AG (CorFlow), a pioneering company in the field of cardiac care targeting microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has approved the company's technology for investigational device exemption (IDE), which allows the pivotal clinical trial to begin at U.S. hospitals. CorFlow will now prepare these clinical trial sites to receive CorFlow systems, undergo training and begin enrolling patients being treated for heart attacks. The IDE Pivotal Trial, MOCA-II, is intended to prospectively validate the diagnostic accuracy of the proprietary CorFlow CoFl system in determining the presence or absence of microvsacular obstruction (MVO) during a primary PCI procedure. The primary endpoint compares the CoFI diagnostic reading to a reference standard of diagnosis by a cardiac MRI scan. The trial is approved to enroll over 200 STEMI patients at prestigious research institutions in both the United States and Europe. Having successfully completed the first-in-human MOCA-I trial in 2024, the MOCA-II study is the next critical step to bringing this unique technology into the hands of interventional cardiologists globally for the rapid diagnosis of MVO in heart attack patients. This in turn can enable new treatments and care pathways to the large MVO patient population with high rates of adverse clinical outcomes today. The CorFlow technology is designed to both diagnose MVO, plus serve as a localized drug delivery system for diagnostic and therapeutic agents, which is being researched independently. According to the US government Centers for Disease Control and Prevention, someone has a heart attack every 30 seconds in the USA, with about 800,000 cases reported annually in the country. Incidence and prevalence are similarly high in Europe. More than half of STEMI heart attack patients are shown to have MVO, and previous research has demonstrated that the presence of MVO is a major driver of adverse events. Currently, there are no technologies approved to diagnose MVO during an acute coronary intervention, and there are no approved therapeutic devices that specifically address MVO in the United States or Europe. Heart attacks and related heart disease remains a leading cause of death and disability worldwide. Paul Mead, CEO of CorFlow, said, 'The long history of interventional cardiology and heart attack care breakthroughs – going back over 100 years – is one of the great success stories of medical care progress, but the pioneers and luminaries of the field all agree that the work is unfinished. The majority of acute STEMI survivors have MVO, and current outcomes for these patients are shockingly poor. We aim to bring this issue to light and show you can do something about it. This milestone brings us all one step closer to delivering on the promise to improving care for these people where we know we can do better.' MOCA-II is being led by world-renowned experts in heart attack care, Dr. Timothy Henry at The Christ Hospital in Cincinnati, Ohio (United States) and Professor Marco Valgimigli at Cardiocentro Ticino Institute, Lugano (Switzerland), who collectively have been published in over 1,000 peer-reviewed manuscripts in cardiovascular research. Dr. Tim Henry said, 'As an interventional cardiologist involved for decades in managing and researching STEMI patients, I am excited to get going on this pivotal trial with technology that could make such a significant impact to the outcome of our patients. I believe strongly that knowing with high confidence who has MVO at the point of care during a primary PCI procedure can make an immediate difference in how we manage our patients.' Professor Valgimigli added, 'Having played a significant part in MOCA-I first in human trial, I am thrilled to see the second-generation technology now available for the pivotal trial and am looking forward to contributing further to the scientific understanding of MVO in real time. While the medical community has diverse opinions on how to treat these patients, there is no question that proper diagnosis is the first step we need. I am optimistic that getting the CorFlow technology approved for everyday use by our peer interventional cardiologists can help move the field forward.' About CorFlow Therapeutics: Headquartered in Baar, Switzerland, with subsidiary operations in both Italy and the United States. The company is venture capital funded with an international VC firm syndicate, most recently with a Series B financing round announced in September 2024. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications for the unique patented technology. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
Entrepreneur
13 hours ago
- Entrepreneur
BII Commits $803 million Worth Impact Investments in Asia
The amount is significantly bigger than that of 2023 when BII invested GBP 245 million in Asian companies and a further GBP 225 million in businesses with operations spanning Asia and Africa. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. British International Investment, the UK's development finance institution and impact investor, has announced its commitment of GBP 626 million (USD 803 million) to Asian businesses in 2024 to support inclusive economic growth and combat the climate emergency. The amount is significantly bigger than that of 2023 when BII invested GBP 245 million in Asian companies and a further GBP 225 million in businesses with operations spanning Asia and Africa. BII has said that the increase in investment was despite the difficult investment environment caused by macroeconomic headwinds. BII's total net assets currently increased to GBP 9.9 billion up from GBP 8.5 billion in 2023, while post-tax profits improved to GBP 213.3m compared with a GBP 44 million loss in 2023. Globally BII invested GBP 1.75 billion in 2024. The figures are contained in BII's Annual Review, which was published today. In total, BII invested USD 903 million in climate finance in 2024, 41 per cent of its overall commitments for the year. This compares with just USD 104 million in 2020. The company's climate finance assets now make up over 26 per cent of its entire portfolio, up from just over 15 per cent in 2020. Over the last three years, BII has invested over USD 2 billion in climate finance. According to BII, based on all direct renewable energy investments in BII's 2023 portfolio, 1.5 million tons of CO2e emissions were avoided on an attributed basis, a 54 per cent year-on-year increase. This was driven by a growing renewable asset base in the portfolio and increases in the amount of renewable power produced. Srini Nagarajan, Managing Director and Head of Asia at BII, said, "Our 2024 investment figures demonstrate our steadfast commitment to our Asian markets as we focus on delivering inclusive economic growth and meeting the challenge of the climate emergency. BII will continue to play a pivotal role in mobilising private capital, particularly for climate finance across South and South-East Asia." BII also made GBP 499 million of gender finance commitments in 2024 and GBP 880 million of commitments to the poorer and most fragile countries across the regions where it invests.
